Rilonacept, an IL-1 inhibitor (IL-1 Trap) that is mainly used for the treatment of gout in children, was recently approved for a phase 3 trial in recurrent pericarditis.426,427 Gevokizumab, an IL-1β binding protein, possesses unique allosteric modulating properties.428 Patients with inflammatory and other diseases may benefit from gevokizumab. This evidence concerns the gene IL1B and gout.